PharmaResources (Shanghai) Co. Ltd. A (301230) - Total Assets
Based on the latest financial reports, PharmaResources (Shanghai) Co. Ltd. A (301230) holds total assets worth CN¥1.32 Billion CNY (≈ $192.55 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of PharmaResources (Shanghai) Co. Ltd. A to assess how comfortably operating cash covers total debt obligations.
PharmaResources (Shanghai) Co. Ltd. A - Total Assets Trend (2020–2025)
This chart illustrates how PharmaResources (Shanghai) Co. Ltd. A's total assets have evolved over time, based on quarterly financial data. See PharmaResources (Shanghai) Co. Ltd. A book value and equity for net asset value and shareholders' equity analysis.
PharmaResources (Shanghai) Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2025)
PharmaResources (Shanghai) Co. Ltd. A's total assets of CN¥1.32 Billion consist of 44.3% current assets and 55.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 4.5% |
| Accounts Receivable | CN¥147.01 Million | 11.2% |
| Inventory | CN¥74.05 Million | 5.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥8.62 Million | 0.7% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how PharmaResources (Shanghai) Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of PharmaResources (Shanghai) Co. Ltd. A.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PharmaResources (Shanghai) Co. Ltd. A's current assets represent 44.3% of total assets in 2025, a decrease from 61.8% in 2020.
- Cash Position: Cash and equivalents constituted 4.5% of total assets in 2025, down from 29.8% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 11.2% of total assets.
PharmaResources (Shanghai) Co. Ltd. A Competitors by Total Assets
Key competitors of PharmaResources (Shanghai) Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
USA | $472.67 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $506.75 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
PharmaResources (Shanghai) Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.76 | 4.36 | 4.63 |
| Quick Ratio | 3.17 | 3.85 | 4.14 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥424.38 Million | CN¥450.40 Million | CN¥607.99 Million |
PharmaResources (Shanghai) Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between PharmaResources (Shanghai) Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.78 |
| Latest Market Cap to Assets Ratio | 0.38 |
| Asset Growth Rate (YoY) | -0.2% |
| Total Assets | CN¥1.31 Billion |
| Market Capitalization | $500.03 Million USD |
Valuation Analysis
Below Book Valuation: The market values PharmaResources (Shanghai) Co. Ltd. A's assets below their book value (0.38x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: PharmaResources (Shanghai) Co. Ltd. A's assets decreased by 0.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for PharmaResources (Shanghai) Co. Ltd. A (2020–2025)
The table below shows the annual total assets of PharmaResources (Shanghai) Co. Ltd. A from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.31 Billion ≈ $192.29 Million |
-0.18% |
| 2024-12-31 | CN¥1.32 Billion ≈ $192.63 Million |
-11.48% |
| 2023-12-31 | CN¥1.49 Billion ≈ $217.62 Million |
+14.29% |
| 2022-12-31 | CN¥1.30 Billion ≈ $190.42 Million |
+133.28% |
| 2021-12-31 | CN¥557.81 Million ≈ $81.62 Million |
+49.15% |
| 2020-12-31 | CN¥373.99 Million ≈ $54.73 Million |
-- |
About PharmaResources (Shanghai) Co. Ltd. A
PharmaResources (Shanghai) Co., Ltd. engages in new drug research, development, and commercial production in China. It offers small molecule drug CRO, CDMO, and CMO. The company also involved in drug discovery, research, and development of pharmaceutical processes; and customized and commercial production of APIs, and key intermediates. It serves global pharmaceutical and biotechnology companies.… Read more